Formulary guidance and transparency from P&T to point of care

Trends That Matter for Biosimilar Medications Cost Savings

Posted by Peter Johnson on May 7, 2020


Biosimilar medications can offer meaningful cost savings for payers, but market and regulatory barriers are still preventing them from realizing their full economic potential, according to a March 31 Johns Hopkins University study funded by the ERISA Industry Committee.

"We could see and empirically prove that patients…tended to be better off if they were on the biosimilar," Mariana Socal, a physician and researcher at the Johns Hopkins Bloomberg School of Public Health and one of the study's authors, tells AIS Health. "They had lower out-of-pocket costs when they were on the biosimilar."
While 16 biosimilars have earned FDA approval, according to the report, most of those drugs are the only biosimilar in their category, creating a duopoly price structure rather than robust market competition with at least three drugs.

Per the report, multiple biosimilars have entered the market for only two drugs, Remicade (infliximab) and Neupogen (filgrastim). The report concludes that, in those categories, biosimilar competition has generated remarkable cost savings and has the potential to generate much more through increased biosimilar use.

For infliximab, the reference biologic Remicade currently has the most covered lives among commercial formularies, while for filgrastim, Zarxio (a biosimilar for Neupogen) is the leader in market access, according to MMIT data.
Increased Biosimilar Use Could Offer Significant Savings for Employers

Subscribe to the MMIT blog for more pharma, provider, and payer perspectives on key topics that affect the healthcare network.

Subscribe for Weekly Perspectives

Topics: Industry Trends, Market Access, Data & Analytics